欧洲特应性皮炎光疗实践调查
该调查由研究作者设计匿名电子问卷,于2021年2月至7月发放给英国和欧洲光疗网络成员,共获27个欧洲国家144名应答者。结果显示NBUVB使用最广(96%),PUVA和UVA1较少用,且起始剂量、增量、疗程、终身限制和年度皮肤评估阈值等处方实践差异很大。结论指出特应性皮炎光疗缺乏共识实践,需进一步研究确定最佳方案。
要点
- NBUVB是欧洲最常用的特应性皮炎光疗,96%应答者使用。
- PUVA和UVA1使用较少,且处方实践在各中心间差异显著。
- 光疗处方参数缺乏共识,提示需高质量随机对照试验确定最佳方案。
核心结论
- NBUVB是欧洲成人和儿童特应性皮炎最常用的光疗,PUVA和UVA1使用较少。
- 特应性皮炎光疗的处方实践差异很大,许多方面缺乏共识。
研究设计与样本
- 研究作者设计匿名电子多选调查,探索光疗处方实践和光疗模式经验。
- 调查发送给英国和欧洲光疗网络成员,应答时间为2021年2月至7月。
- 共144名应答者来自27个欧洲国家完成调查。
主要发现
- NBUVB使用最广泛,n=138(96%)。
- 家庭NBUVB在8/27个国家可用(25/144应答者,17%)。
- 口服PUVA比浴PUVA更广泛可用(n=106,74% vs. n=60,42%),且主要用于成人患者。
- 49/144(34%)应答者可使用UVA1。
- 对于NBUVB,96%成人患者和82%儿童患者会考虑光疗替代系统治疗;对于PUVA,40%成人患者和3%儿童患者会考虑。
关键数值与推荐
- 起始剂量、标准剂量增量、疗程长度、治疗终身限制和年度皮肤评估阈值在应答者间存在差异。
临床怎么用
- 欧洲特应性皮炎光疗以NBUVB为主,PUVA和UVA1使用较少。
- 临床处方光疗时需注意起始剂量、增量、疗程和终身限制等参数缺乏共识。
局限性
- 光疗疗效、生活质量影响、成本效果及真实使用中短期和长期安全性的证据薄弱。
- 调查为匿名电子问卷,处方实践差异提示缺乏共识实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Phototherapy is used to treat atopic dermatitis (AD). Evidence for its efficacy, impact on quality of life, cost-effectiveness and short- and long-term safety with real-life usage is weak. OBJECTIVES: We established a taskforce to examine how phototherapy is currently being used as a treatment for AD across the United Kingdom and Europe to inform our understanding and guide future research into management of patients with AD using UV-based phototherapies. METHODS: An anonymous electronic multiple-response survey exploring phototherapy prescribing practices and experience of phototherapy modalities was developed by the study authors and sent to members of phototherapy networks from the United Kingdom and Europe. Responses were received between February and July 2021. RESULTS: About 144 respondents from 27 European countries completed the survey. NBUVB was the most widely used [n = 138 (96%)]. Home-based NBUVB was available in 8/27 countries (25/144 respondents, 17%). Oral psoralen-UVA (PUVA) was more widely available than bath PUVA (n = 106, 74% vs. n = 60, 42%) and used mainly in adult patients. 49/144 (34%) of respondents had access to UVA1. Phototherapy would be considered instead of systemic treatment in 96% of adults and 82% of children for NBUVB, versus 40% of adults and 3% of children for PUVA. Starting doses, standard dosing increments, length of treatment courses, lifetime limits for treatments and thresholds for performing annual skin assessments varied between responders. CONCLUSIONS: NBUVB was the most widely used phototherapy for AD in adult and paediatric patients, while PUVA and UVA1 were less used. Prescribing practices varied considerably, highlighting the lack of consensus practice in many different aspects of phototherapy for the treatment of AD in children and adults. This indicates that further studies are required to determine optimal phototherapeutic regimens for AD and informs our understanding of parameters that should be included in future high-quality randomized controlled trials (RCT) of phototherapy.
引用
- Steyn M, Gerbens LAA, Spuls PI, et al. Phototherapy for atopic dermatitis: A survey of European practice. J Eur Acad Dermatol Venereol. 2023. PMID: 38011002. doi:10.1111/jdv.19638
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。